/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR
FOR DISSEMINATION IN THE UNITED
STATES/
OTTAWA, Jan. 22, 2020 /CNW Telbec/ - Tetra
Bio-Pharma Inc.(TSXV:TBP) ("Tetra" or "TBP") announces a correction
to its press release entitled "TETRA BIO-PHARMA ANNOUNCES
$10.0 MILLION BOUGHT DEAL
OFFERING" issued today (the "Initial Press
Release").
The Initial Press Release incorrectly stated that the Offering,
as defined therein, will be completed by way of a short form
prospectus to be filed in all of the provinces and territories of
Canada other than Quebec. However the Offering will be conducted
in all the provinces of Canada,
including Quebec, but excluding
the territories of Canada. This
correction does not change any other information reported in the
Initial Press Release.
About Tetra Bio-Pharma
Tetra Bio-Pharma
(TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health
Canada approved, and FDA reviewed, clinical program aimed at
bringing novel prescription drugs and treatments to patients and
their healthcare providers. The Company has several subsidiaries
engaged in the development of an advanced and growing pipeline of
Bio Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is focused on
providing rigorous scientific validation and safety data required
for inclusion into the existing bio pharma industry by regulators,
physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of this
product or any other product, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma Inc.